Literature DB >> 9508302

Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.

F Bouche1, W Ammerlaan, F Berthet, S Houard, F Schneider, C P Muller.   

Abstract

Recombinant hemagglutinin (H) protein of the measles virus (MV) was produced in mammalian cells with a high-yield expression system based on the Semliki Forest virus replicon. Crude membrane preparations of H protein-transfected BHK-21 cells were used to coat microtiter plates to measure specific immunoglobulin G antibodies in 228 serologically defined serum samples mainly from measles late-convalescent adults. The titers by the enzyme-linked immunosorbent assay for the H protein (H-ELISA) closely correlated with neutralization test (NT) titers (R2 = 0.66), hemagglutination inhibition test (HI) titers (R2 = 0.64), with the titers from a certified commercial ELISA based on whole MV-infected cells (MV-ELISA; R2 = 0.45). The correlations described above were better than those of the commercial MV-ELISA titers with the NT (R2 = 0.52) or HI (R2 = 0.48) titers. By using the 2nd International Standard for anti-measles serum, the detection level of the assay corresponds to 215 mIU/ml for undiluted serum, which corresponds to the estimated threshold for protective immunity. The specificity, accuracy, and positive predictive value were, in general, better for the H-ELISA than for a commercial MV-ELISA, independent of whether HI, NT, or HI and NT were used as "gold standards." In contrast, the H-ELISA proved to be slightly less sensitive than the MV-ELISA (sensitivities, 98.6 versus 99.5%, respectively; P was not significant). The assays did not differ significantly in the number of serum samples with positive HI and NT results (n = 212) which measured false negative (H-ELISA, 2 of 212 [0.94%]; MV-ELISA, 1 of 212 [0.47%]), but the H-ELISA detected significantly more measles-susceptible individuals than the MV-ELISA (10 of 11 versus 3 of 11, respectively; P < 0.05) among the individuals whose sera had negative HI and NT results. Our data demonstrate that the H-protein preparation that we describe could be a cost-effective alternative to current whole-virus-based ELISAs for surveillance for immunity to measles and that such an assay could be more efficient in detecting susceptibility to measles. Furthermore, unlike whole MV-based antigens, H-protein would also be suitable for use in the development of a simple field test for the diagnosis of measles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508302      PMCID: PMC104615          DOI: 10.1128/JCM.36.3.721-726.1998

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  48 in total

1.  Use of Concentrated Human Serum gamma-Globulin in the Prevention and Attenuation of Measles.

Authors:  C A Janeway
Journal:  Bull N Y Acad Med       Date:  1945-04

2.  Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure.

Authors:  P Albrecht; F A Ennis; E J Saltzman; S Krugman
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

3.  Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status.

Authors:  P W Neumann; J M Weber; A G Jessamine; M V O'Shaughnessy
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

4.  Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell-mediated immunity.

Authors:  A I Cardoso; M Blixenkrone-Moller; J Fayolle; M Liu; R Buckland; T F Wild
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

5.  Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus.

Authors:  D D Erdman; L J Anderson; D R Adams; J A Stewart; L E Markowitz; W J Bellini
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

6.  Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.

Authors:  T F Wild; A Bernard; D Spehner; R Drillien
Journal:  J Gen Virol       Date:  1992-02       Impact factor: 3.891

7.  Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays.

Authors:  K B Hummel; D D Erdman; J Heath; W J Bellini
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

8.  Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.

Authors:  J Taylor; R Weinberg; J Tartaglia; C Richardson; G Alkhatib; D Briedis; M Appel; E Norton; E Paoletti
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

9.  Intracellular processing and antigenic maturation of measles virus hemagglutinin protein.

Authors:  A Hu; J Kövamees; E Norrby
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Production of measles nucleoprotein in different expression systems and its use as a diagnostic reagent.

Authors:  A Warnes; A R Fooks; J R Stephenson
Journal:  J Virol Methods       Date:  1994-10       Impact factor: 2.014

View more
  8 in total

1.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  New immunofluorescence assays for detection of Human herpesvirus 8-specific antibodies.

Authors:  N Inoue; E C Mar; S C Dollard; C P Pau; Q Zheng; P E Pellett
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Robert A Vierkant; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2008-05-07

4.  Evaluation of hemagglutinin protein-specific immunoglobulin M for diagnosis of measles by an enzyme-linked immunosorbent assay based on recombinant protein produced in a high-efficiency mammalian expression system.

Authors:  F B Bouche; N H Brons; S Houard; F Schneider; C P Muller
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

5.  Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin.

Authors:  E Marquet-Blouin; F B Bouche; A Steinmetz; C P Muller
Journal:  Plant Mol Biol       Date:  2003-03       Impact factor: 4.076

6.  Saliva as an alternative specimen for detection of Schmallenberg virus-specific antibodies in bovines.

Authors:  Justas Lazutka; Aliona Spakova; Vilimas Sereika; Raimundas Lelesius; Kestutis Sasnauskas; Rasa Petraityte-Burneikiene
Journal:  BMC Vet Res       Date:  2015-09-15       Impact factor: 2.741

7.  Generation of recombinant Schmallenberg virus nucleocapsid protein in yeast and development of virus-specific monoclonal antibodies.

Authors:  Justas Lazutka; Aurelija Zvirbliene; Indre Dalgediene; Rasa Petraityte-Burneikiene; Aliona Spakova; Vilimas Sereika; Raimundas Lelesius; Kerstin Wernike; Martin Beer; Kestutis Sasnauskas
Journal:  J Immunol Res       Date:  2014-05-29       Impact factor: 4.818

8.  Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.

Authors:  Iana H Haralambieva; Whitney L Simon; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  Viruses       Date:  2015-03-10       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.